ClinicalTrials.gg
CompletedNCT02911948DUAL™ II JapanUpdated Apr 9, 2021Results posted

A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs

A Phase 3 interventional study of Insulin degludec/liraglutide and Insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 38 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-04-09.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
49th of 70
210 · median 384
Started
2016
with 5 others
Phase 3
49 of 70
2 open now
Registered
51st of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 49th largest by enrollment, is one of 6 that started in 2016, is one of 49 in phase 3, and was the 51st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide and insulin degludec both in combination with metformin in Japanese subjects with type 2 diabetes mellitus inadequately controlled with basal or pre-mix/combination insulin therapy and oral anti-diabetic drugs.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 210 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female Japanese subjects, age at least 20 years at the time of signing
  • T2DM (type 2 diabetes mellitus) subjects (diagnosed clinically) for at least 6 months prior to screening
  • (glycosylated ) 7.5-11.0 per cent [58 mmol/mol-97 mmol/mol] (both inclusive) by central laboratory analysis
  • Subjects on stable daily insulin doses for at least 60 days prior to screening administered once or twice daily, either as basal insulin (e.g. IDeg, insulin glargine, insulin detemir, NPH insulin) or pre-mix/combination insulin (e.g. biphasic insulin aspart, insulin degludec/insulin aspart). Total daily insulin dose in the previous 60 days should be within 20-50 units, both inclusive, and on the day of screening, but fluctuations of plus/minus 20 per cent within the 60 days prior to screening are acceptable. The specified insulin treatment should be administered in combination with a stable daily dose of metformin within current approved Japanese label for at least 60 days prior to screening - additionally, the anti-diabetic treatment can be with or without a stable daily dose of one of the following other OADs (oral anti-diabetic drug): SU (sulfonylureas), glinides, alpha-glucosidase inhibitor, SGLT2i (sodium glucose co-transporter 2 inhibitor) or TZD (thiazolidinedione) within current approved Japanese label for at least 60 days prior to screening
  • (BMI) equal or above 23 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Receipt of any medicinal product (IMP) within 30 days before screening
  • Use of any anti-diabetic drug in a period of 60 days before screening (except premix/ combination or basal insulin, metformin, SU, glinides, α-GI, SGLT2i, or TZD) or anticipated change in concomitant medication, which in the investigators opinion could interfere with glucose metabolism (e.g. systemic or bolus insulin)
  • Treatment with glucagon-like peptide-1 (GLP-1) receptor agonist during the last 60 days prior to screening and furthermore, the discontinuation of GLP-1 receptor agonist at any point in time must not have been due to safety concerns, tolerability issues or lack of efficacy, as judged by the investigator
  • Treatment with dipetidyl peptidase-4 (DPP-4) inhibitors during the last 60 days prior to screening - Impaired liver function, defined as (ALT) or aspartate aminotransferase (AST) equal or above 2.5 times
  • Renal impairment estimated (eGFR) below 60 mL/min/1.73m\^2 as per Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
  • Screening calcitonin equal or above 50 ng/L
  • History of pancreatitis (acute or chronic)
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)
  • Subjects presently classified as being in (NYHA) Class IV
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    Insulin degludec/liraglutide

    Drug: Insulin degludec/liraglutide

  • Active comparator
    Insulin degludec

    Drug: Insulin degludec

Interventions

07

What researchers measure

Primary outcomes

  1. Change in Glycosylated Haemoglobin (HbA1c)

    Change from baseline (week 0) in HbA1c after 26 weeks of treatment.

    Time frame: week 0, week 26

Secondary outcomes

  1. Change in Body Weight

    Change from baseline (week 0) in body weight after 26 weeks of treatment.

    Time frame: week 0, week 26

  2. Change in Fasting Plasma Glucose (FPG)

    Change from baseline (week 0) in FPG after 26 weeks of treatment.

    Time frame: week 0, week 26

  3. Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes

    Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with or without symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

    Time frame: During 26 weeks of treatment

  4. Daily Insulin Dose

    Actual daily total insulin dose after 26 weeks.

    Time frame: After 26 weeks

  5. Responder (Yes/no): HbA1c Less Than 7.0%

    Number of subjects with HbA1c less than 7.0% after 26 weeks.

    Time frame: After 26 weeks

  6. Responder (Yes/no): HbA1c Less Than 7.0% and Without Weight Gain

    Number of subjects with HbA1c less than 7.0% and without weight gain after 26 weeks.

    Time frame: After 26 weeks

  7. Responder (Yes/no): HbA1c Less Than 7.0% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment

    Number of subjects with HbA1c less than 7.0% after 26 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

    Time frame: After 26 weeks

  8. Responder (Yes/no): HbA1c Less Than 7.0% and Without Weight Gain and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment

    Number of subjects with HbA1c less than 7.0% and no weight gain after 26 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

    Time frame: After 26 weeks

  9. Responder (Yes/no): HbA1c Less Than or Equal to 6.5%

    Number of subjects with HbA1c less than or equal to 6.5% after 26 weeks.

    Time frame: After 26 weeks

  10. Responder (Yes/no): HbA1c Less Than or Equal to 6.5% and Without Weight Gain

    Number of subjects with HbA1c less than or equal to 6.5% and without weight gain

    Time frame: After 26 weeks

  11. Responder (Yes/no): HbA1c Less Than or Equal to 6.5% Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment

    Number of subjects with HbA1c less than or equal to 6.5% after 26 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

    Time frame: After 26 weeks

  12. Responder (Yes/no): HbA1c Less Than or Equal to 6.5% and Without Weight Gain and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment

    Number of subjects with HbA1c less than or equal to 6.5% and no weight gain after 26 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

    Time frame: After 26 weeks

  13. Change in Waist Circumference

    Change from baseline (week 0) in waist circumference after 26 weeks of treatment.

    Time frame: week 0, week 26

  14. Change in Blood Pressure (Systolic and Diastolic)

    Change from baseline in blood pressure (systolic and diastolic) after 26 weeks of treatment.

    Time frame: week 0, week 26

  15. Self-measured Blood Glucose (SMBG) 9-point Profile (Individual Points in the Profile)

    Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day.

    Time frame: After 26 weeks

  16. Change in SMBG 9-point Profile: Mean of the 9-point Profile

    Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. Mean of the 9-point profile was defined as the area under the profile (calculated using the trapezoidal method) divided by the measurement time.

    Time frame: Week 0, week 26

  17. Change in SMBG 9-point Profile: Mean of Postprandial Plasma Glucose Increments (From Before Meal to 90 Minutes After Breakfast, Lunch and Dinner)

    Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. The mean increment over all meals was derived as the mean of all available meal increments.

    Time frame: Week 0, week 26

  18. Fasting Lipid Profile

    Lipid profile includes total cholesterol, low density lipoprotein cholesterol (LDL cholesterol), high density lipoprotein cholesterol (HDL cholesterol), very low density lipoprotein cholesterol (VLDL cholesterol), triglycerides and free fatty acids. Lipid profile parameters are represented as ratio to baseline values.

    Time frame: Week 0, week 26

  19. Number of Treatment Emergent Adverse Events (TEAE)

    Treatment emergent adverse event is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. If the event had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last drug date, then this event was considered as a TEAE.

    Time frame: During 26 weeks of treatment

  20. Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

    Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

    Time frame: During 26 weeks of treatment

  21. Number of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA) Definition

    Results represent total number of treatment emergent hypoglycaemic episodes that fall under ADA's definition of hypoglycaemia. ADA's definition of hypoglycaemia includes following categories: 1. Severe hypoglycaemia 2. Documented symptomatic hypoglycaemia 3. Asymptomatic hypoglycaemia 4. Probable symptomatic hypoglycaemia 5. Pseudo-hypoglycaemia. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product.

    Time frame: During 26 weeks of treatment

  22. Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

    Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Nocturnal period: The period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

    Time frame: During 26 weeks of treatment

  23. Change in Clinical Evaluation: Fundoscopy or Fundus Photography

    The result of the fundus photography/dilated fundoscopy was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' fundoscopy/fundus photography results at screening (week -2 to week 0) and week 26.

    Time frame: Screening (week -2 to week 0), week 26

  24. Change in Clinical Evaluation: Electrocardiogram (ECG)

    The result of the ECG was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' ECG results at screening (week -2 to week 0) and week 26.

    Time frame: Screening (week -2 to week 0), week 26

  25. Change in Pulse

    Change in pulse after 26 weeks of treatment.

    Time frame: Week 0, week 26

  26. Change From Baseline in Patient Reported Outcomes (PROs) of Treatment: Diabetes Therapy-Related Quality of Life (DTR-QOL)Questionnaire

    For the DTR-QOL questionnaire, change from baseline in the 'Total score' and the following four 'Domain scores' were analysed: 1. Burden on social activities and daily activities 2. Anxiety and dissatisfaction with treatment 3. Hypoglycaemia 4. Satisfaction with treatment. The scoring range of 'Total score' was converted to 0-100 (best case response = 100; worst case response = 0). The scoring range for each of four domains was converted to 0-100 (best case response = 100; worst case response = 0).

    Time frame: week 0, week 26

  27. Change From Baseline in Patient Reported Outcomes (PROs) of Treatment: EuroQol-5D (EQ-5D-5L) Questionnaire

    Overall health state was rated by patients using the EQ-5D-5L visual analogue scale (VAS) and the EQ-5D-5L index score. The EQ-5D-5L VAS is a vertical scale where patients can rank their health from 0 (worst health imaginable) to 100 (best health imaginable). The EQ-5D-5L index score was calculated based on the 5 dimensions, i.e., mobility, self-care, usual activities (e.g., work, study), pain/discomfort and anxiety/depression with five response levels for each dimension, i.e., no problems, slight problems, moderate problems, severe problems and extreme problems. The scores from 5 dimensions are then converted to the EQ-5D-5L index score scale: 0 - 1 (full health/best-case response = 1; death/worst-case response = 0).

    Time frame: week 0, week 26

08

Results

Posted Mar 11, 2019

Participant flow

The trial was conducted at 38 sites in Japan as follows: 38 sites screened and 37 sites randomised subjects.

Participant flow — Overall Study
MilestoneInsulin Degludec/LiraglutideInsulin Degludec
Started105105
Completed10598
Not completed07
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject02
Withdrew: Lack of efficacy01
Withdrew: Unclassified03

Outcome measures

PrimaryChange in Glycosylated Haemoglobin (HbA1c)

Change from baseline (week 0) in HbA1c after 26 weeks of treatment.

Time frame:
week 0, week 26
Reported as:
Mean · Percentage of HbA1c
Change in Glycosylated Haemoglobin (HbA1c)
Percentage of HbA1cInsulin Degludec/LiraglutideInsulin Degludec
Change in Glycosylated Haemoglobin (HbA1c)-1.95 ± 1.01-0.65 ± 0.98
Statistical analysis
  • Insulin Degludec/Liraglutide vs Insulin Degludec · ANCOVA · p = <0.0001 · Treatment contrast: -1.28 · 95% CI -1.50 to -1.06
SecondaryChange in Body Weight

Change from baseline (week 0) in body weight after 26 weeks of treatment.

Time frame:
week 0, week 26
Reported as:
Mean · Kg
Change in Body Weight
KgInsulin Degludec/LiraglutideInsulin Degludec
Change in Body Weight-0.7 ± 3.50.7 ± 2.7
SecondaryChange in Fasting Plasma Glucose (FPG)

Change from baseline (week 0) in FPG after 26 weeks of treatment.

Time frame:
week 0, week 26
Reported as:
Mean · mmol/L
Change in Fasting Plasma Glucose (FPG)
mmol/LInsulin Degludec/LiraglutideInsulin Degludec
Change in Fasting Plasma Glucose (FPG)-2.81 ± 3.17-2.29 ± 2.68
SecondaryNumber of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes

Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with or without symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

Time frame:
During 26 weeks of treatment
Reported as:
Number · Number of episodes
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes
Number of episodesInsulin Degludec/LiraglutideInsulin Degludec
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes124109
SecondaryDaily Insulin Dose

Actual daily total insulin dose after 26 weeks.

Time frame:
After 26 weeks
Reported as:
Mean · Units
Daily Insulin Dose
UnitsInsulin Degludec/LiraglutideInsulin Degludec
Daily Insulin Dose37.6 ± 11.441.2 ± 11.5
SecondaryResponder (Yes/no): HbA1c Less Than 7.0%

Number of subjects with HbA1c less than 7.0% after 26 weeks.

Time frame:
After 26 weeks
Reported as:
Count of participants · Participants
Responder (Yes/no): HbA1c Less Than 7.0%
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Yes7523
No3082
SecondaryResponder (Yes/no): HbA1c Less Than 7.0% and Without Weight Gain

Number of subjects with HbA1c less than 7.0% and without weight gain after 26 weeks.

Time frame:
After 26 weeks
Reported as:
Count of participants · Participants
Responder (Yes/no): HbA1c Less Than 7.0% and Without Weight Gain
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Yes509
No5596
SecondaryResponder (Yes/no): HbA1c Less Than 7.0% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment

Number of subjects with HbA1c less than 7.0% after 26 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

Time frame:
After 26 weeks
Reported as:
Count of participants · Participants
Responder (Yes/no): HbA1c Less Than 7.0% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Yes7020
No3581
SecondaryResponder (Yes/no): HbA1c Less Than 7.0% and Without Weight Gain and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment

Number of subjects with HbA1c less than 7.0% and no weight gain after 26 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

Time frame:
After 26 weeks
Reported as:
Count of participants · Participants
Responder (Yes/no): HbA1c Less Than 7.0% and Without Weight Gain and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Yes497
No5694
SecondaryResponder (Yes/no): HbA1c Less Than or Equal to 6.5%

Number of subjects with HbA1c less than or equal to 6.5% after 26 weeks.

Time frame:
After 26 weeks
Reported as:
Count of participants · Participants
Responder (Yes/no): HbA1c Less Than or Equal to 6.5%
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Yes579
No4896
SecondaryResponder (Yes/no): HbA1c Less Than or Equal to 6.5% and Without Weight Gain

Number of subjects with HbA1c less than or equal to 6.5% and without weight gain

Time frame:
After 26 weeks
Reported as:
Count of participants · Participants
Responder (Yes/no): HbA1c Less Than or Equal to 6.5% and Without Weight Gain
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Yes384
No67101
SecondaryResponder (Yes/no): HbA1c Less Than or Equal to 6.5% Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment

Number of subjects with HbA1c less than or equal to 6.5% after 26 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

Time frame:
After 26 weeks
Reported as:
Count of participants · Participants
Responder (Yes/no): HbA1c Less Than or Equal to 6.5% Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Yes538
No5293
SecondaryResponder (Yes/no): HbA1c Less Than or Equal to 6.5% and Without Weight Gain and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment

Number of subjects with HbA1c less than or equal to 6.5% and no weight gain after 26 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.

Time frame:
After 26 weeks
Reported as:
Count of participants · Participants
Responder (Yes/no): HbA1c Less Than or Equal to 6.5% and Without Weight Gain and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Yes373
No6898
SecondaryChange in Waist Circumference

Change from baseline (week 0) in waist circumference after 26 weeks of treatment.

Time frame:
week 0, week 26
Reported as:
Mean · cm
Change in Waist Circumference
cmInsulin Degludec/LiraglutideInsulin Degludec
Change in Waist Circumference-0.6 ± 3.80.1 ± 3.8
SecondaryChange in Blood Pressure (Systolic and Diastolic)

Change from baseline in blood pressure (systolic and diastolic) after 26 weeks of treatment.

Time frame:
week 0, week 26
Reported as:
Mean · mmHg
Change in Blood Pressure (Systolic and Diastolic)
mmHgInsulin Degludec/LiraglutideInsulin Degludec
Systolic blood pressure-0.6 ± 14.70.9 ± 13.6
Diastolic blood pressure0.9 ± 9.01.2 ± 9.0
SecondarySelf-measured Blood Glucose (SMBG) 9-point Profile (Individual Points in the Profile)

Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day.

Time frame:
After 26 weeks
Reported as:
Mean · mmol/L
Self-measured Blood Glucose (SMBG) 9-point Profile (Individual Points in the Profile)
mmol/LInsulin Degludec/LiraglutideInsulin Degludec
Before breakfast6.59 ± 2.326.53 ± 2.19
90 minutes after start of breakfast11.00 ± 3.6712.02 ± 3.57
Before lunch7.22 ± 2.968.49 ± 3.75
90 minutes after start of lunch10.59 ± 3.1712.84 ± 3.65
Before dinner7.39 ± 2.568.60 ± 3.97
90 minutes after start of dinner11.09 ± 3.2413.27 ± 4.05
At Bedtime9.57 ± 3.5411.98 ± 4.17
At 4:00 a.m.6.75 ± 1.987.72 ± 2.90
Before breakfast the following day6.14 ± 1.686.40 ± 2.06
SecondaryChange in SMBG 9-point Profile: Mean of the 9-point Profile

Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. Mean of the 9-point profile was defined as the area under the profile (calculated using the trapezoidal method) divided by the measurement time.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change in SMBG 9-point Profile: Mean of the 9-point Profile
mmol/LInsulin Degludec/LiraglutideInsulin Degludec
Change in SMBG 9-point Profile: Mean of the 9-point Profile-2.90 ± 2.87-1.11 ± 2.68
SecondaryChange in SMBG 9-point Profile: Mean of Postprandial Plasma Glucose Increments (From Before Meal to 90 Minutes After Breakfast, Lunch and Dinner)

Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. The mean increment over all meals was derived as the mean of all available meal increments.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change in SMBG 9-point Profile: Mean of Postprandial Plasma Glucose Increments (From Before Meal to 90 Minutes After Breakfast, Lunch and Dinner)
mmol/LInsulin Degludec/LiraglutideInsulin Degludec
Change in SMBG 9-point Profile: Mean of Postprandial Plasma Glucose Increments (From Before Meal to 90 Minutes After Breakfast, Lunch and Dinner)-0.76 ± 3.000.70 ± 2.93
SecondaryFasting Lipid Profile

Lipid profile includes total cholesterol, low density lipoprotein cholesterol (LDL cholesterol), high density lipoprotein cholesterol (HDL cholesterol), very low density lipoprotein cholesterol (VLDL cholesterol), triglycerides and free fatty acids. Lipid profile parameters are represented as ratio to baseline values.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · Ratio
Fasting Lipid Profile
RatioInsulin Degludec/LiraglutideInsulin Degludec
Total cholesterol0.90 ± 15.90.96 ± 13.0
HDL cholesterol0.90 ± 17.50.95 ± 12.2
LDL cholesterol0.86 ± 26.70.95 ± 21.5
VLDL cholesterol1.02 ± 50.50.97 ± 38.2
Triglycerides1.02 ± 58.50.97 ± 39.3
Free fatty acids0.86 ± 67.70.77 ± 55.3
SecondaryNumber of Treatment Emergent Adverse Events (TEAE)

Treatment emergent adverse event is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. If the event had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last drug date, then this event was considered as a TEAE.

Time frame:
During 26 weeks of treatment
Reported as:
Number · Number of events
Number of Treatment Emergent Adverse Events (TEAE)
Number of eventsInsulin Degludec/LiraglutideInsulin Degludec
Number of Treatment Emergent Adverse Events (TEAE)280210
SecondaryNumber of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

Time frame:
During 26 weeks of treatment
Reported as:
Number · Number of episodes
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Number of episodesInsulin Degludec/LiraglutideInsulin Degludec
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes5243
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA) Definition

Results represent total number of treatment emergent hypoglycaemic episodes that fall under ADA's definition of hypoglycaemia. ADA's definition of hypoglycaemia includes following categories: 1. Severe hypoglycaemia 2. Documented symptomatic hypoglycaemia 3. Asymptomatic hypoglycaemia 4. Probable symptomatic hypoglycaemia 5. Pseudo-hypoglycaemia. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product.

Time frame:
During 26 weeks of treatment
Reported as:
Number · Number of episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA) Definition
Number of episodesInsulin Degludec/LiraglutideInsulin Degludec
Number of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA) Definition780717
SecondaryNumber of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes

Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Nocturnal period: The period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

Time frame:
During 26 weeks of treatment
Reported as:
Number · Number of episodes
Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Number of episodesInsulin Degludec/LiraglutideInsulin Degludec
Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes48
SecondaryChange in Clinical Evaluation: Fundoscopy or Fundus Photography

The result of the fundus photography/dilated fundoscopy was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' fundoscopy/fundus photography results at screening (week -2 to week 0) and week 26.

Time frame:
Screening (week -2 to week 0), week 26
Reported as:
Count of participants · Participants
Change in Clinical Evaluation: Fundoscopy or Fundus Photography
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
Left eye - at screening visit - normal5370
Left eye - at screening visit - Abn, NCS65
Left eye - at screening visit - Abn, CS4630
Left eye - week 26 - normal5464
Left eye - week 26 - Abn, NCS77
Left eye - week 26 - Abn, CS4434
Right eye - at screening visit - normal5572
Right eye - at screening visit - Abn, NCS76
Right eye - at screening visit - Abn, CS4327
Right eye - week 26 - normal5269
Right eye - week 26 - Abn, NCS86
Right eye - week 26 - Abn, CS4530
SecondaryChange in Clinical Evaluation: Electrocardiogram (ECG)

The result of the ECG was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' ECG results at screening (week -2 to week 0) and week 26.

Time frame:
Screening (week -2 to week 0), week 26
Reported as:
Count of participants · Participants
Change in Clinical Evaluation: Electrocardiogram (ECG)
ParticipantsInsulin Degludec/LiraglutideInsulin Degludec
At screening visit - normal8082
At screening visit - Abn, NCS2018
At screening visit - Abn, CS55
Week 26 -normal8282
Week 26 - Abn, NCS1720
Week 26 - Abn, CS63
SecondaryChange in Pulse

Change in pulse after 26 weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · beats per minute
Change in Pulse
beats per minuteInsulin Degludec/LiraglutideInsulin Degludec
Change in Pulse6.1 ± 11.0-0.2 ± 7.1
SecondaryChange From Baseline in Patient Reported Outcomes (PROs) of Treatment: Diabetes Therapy-Related Quality of Life (DTR-QOL)Questionnaire

For the DTR-QOL questionnaire, change from baseline in the 'Total score' and the following four 'Domain scores' were analysed: 1. Burden on social activities and daily activities 2. Anxiety and dissatisfaction with treatment 3. Hypoglycaemia 4. Satisfaction with treatment. The scoring range of 'Total score' was converted to 0-100 (best case response = 100; worst case response = 0). The scoring range for each of four domains was converted to 0-100 (best case response = 100; worst case response = 0).

Time frame:
week 0, week 26
Reported as:
Mean · Score on a scale
Change From Baseline in Patient Reported Outcomes (PROs) of Treatment: Diabetes Therapy-Related Quality of Life (DTR-QOL)Questionnaire
Score on a scaleInsulin Degludec/LiraglutideInsulin Degludec
Total score7.9 ± 14.80.1 ± 13.4
Burden on social activities and daily activities5.7 ± 17.30.6 ± 17.1
Anxiety and dissatisfaction with treatment12.9 ± 20.80.4 ± 17.2
Hypoglycaemia-2.6 ± 25.5-1.6 ± 25.9
Satisfaction with treatment15.8 ± 22.5-0.4 ± 24.7
SecondaryChange From Baseline in Patient Reported Outcomes (PROs) of Treatment: EuroQol-5D (EQ-5D-5L) Questionnaire

Overall health state was rated by patients using the EQ-5D-5L visual analogue scale (VAS) and the EQ-5D-5L index score. The EQ-5D-5L VAS is a vertical scale where patients can rank their health from 0 (worst health imaginable) to 100 (best health imaginable). The EQ-5D-5L index score was calculated based on the 5 dimensions, i.e., mobility, self-care, usual activities (e.g., work, study), pain/discomfort and anxiety/depression with five response levels for each dimension, i.e., no problems, slight problems, moderate problems, severe problems and extreme problems. The scores from 5 dimensions are then converted to the EQ-5D-5L index score scale: 0 - 1 (full health/best-case response = 1; death/worst-case response = 0).

Time frame:
week 0, week 26
Reported as:
Mean · Score on a scale
Change From Baseline in Patient Reported Outcomes (PROs) of Treatment: EuroQol-5D (EQ-5D-5L) Questionnaire
Score on a scaleInsulin Degludec/LiraglutideInsulin Degludec
Change in VAS score6.3 ± 17.8-1.0 ± 15.5
Index score0.02 ± 0.08-0.01 ± 0.11

Adverse events

Collected over Week 0 (randomisation) to week 26 (end of treatment) and 7 days after end of treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin Degludec/Liraglutide0/105 (0%)3/105 (2.9%)54/105 (51.4%)
Insulin Degludec0/105 (0%)4/105 (3.8%)48/105 (45.7%)
Most frequent serious events
Most frequent serious events
EventInsulin Degludec/LiraglutideInsulin Degludec
Acute myocardial infarctionCardiac disorders1/1050/105
Cardiac failure congestiveCardiac disorders1/1050/105
Cholecystitis acuteHepatobiliary disorders0/1051/105
GastroenteritisInfections and infestations1/1050/105
Hip fractureInjury, poisoning and procedural complications1/1050/105
Loss of consciousnessNervous system disorders0/1051/105
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1051/105
Renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1051/105
Retinal detachmentEye disorders0/1051/105
Most frequent other events
Most frequent other events
EventInsulin Degludec/LiraglutideInsulin Degludec
Viral upper respiratory tract infectionInfections and infestations21/10524/105
Diabetic retinopathyEye disorders17/10517/105
DiarrhoeaGastrointestinal disorders15/1055/105
NauseaGastrointestinal disorders10/1054/105
ConstipationGastrointestinal disorders9/1054/105
VomitingGastrointestinal disorders9/1052/105
Abdominal discomfortGastrointestinal disorders8/1055/105
Decreased appetiteMetabolism and nutrition disorders8/1050/105

Baseline characteristics

Full Analysis Set (FAS) included all randomised subjects (210 subjects).

Age, Continuous
Age, Continuous(Years)Insulin Degludec/LiraglutideInsulin DegludecTotal
Mean56.6 ± 10.455.5 ± 10.056.0 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Degludec/LiraglutideInsulin DegludecTotal
Female354277
Male7063133
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insulin Degludec/LiraglutideInsulin DegludecTotal
Hispanic or Latino000
Not Hispanic or Latino000
Unknown or Not Reported105105210
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin Degludec/LiraglutideInsulin DegludecTotal
American Indian or Alaska Native000
Asian105105210
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Glycosylated Haemoglobin (HbA1c)
Glycosylated Haemoglobin (HbA1c)(Percentage of HbA1c)Insulin Degludec/LiraglutideInsulin DegludecTotal
Mean8.61 ± 0.888.56 ± 0.808.58 ± 0.84
09

Study locations

38 sites
  • Novo Nordisk Investigational Site
    Asahikawa-shi, Hokkaido, 078-8211, Japan
  • Novo Nordisk Investigational Site
    Chigasaki-shi, Kanagawa, 253-0044, Japan
  • Novo Nordisk Investigational Site
    Chitose, Hokkaido, 066-0032, Japan
  • Novo Nordisk Investigational Site
    Chiyoda-ku, Tokyo, 101-0024, Japan
  • Novo Nordisk Investigational Site
    Fujisawa-shi, Kanagawa, 251-0041, Japan
  • Novo Nordisk Investigational Site
    Fukui-shi, Fukui, 918-8503, Japan
  • Novo Nordisk Investigational Site
    Fukuoka-shi, Fukuoka, 810-0001, Japan
  • Novo Nordisk Investigational Site
    Fukuoka-shi, Fukuoka, 819-0006, Japan
  • Novo Nordisk Investigational Site
    Fukuoka, 830 8522, Japan
  • Novo Nordisk Investigational Site
    Fukushima, 963-8851, Japan
  • Novo Nordisk Investigational Site
    Hokkaido, 060-0062, Japan
  • Novo Nordisk Investigational Site
    Ibaraki, 311-0113, Japan
  • Novo Nordisk Investigational Site
    Kanagawa, 235-0045, Japan
  • Novo Nordisk Investigational Site
    Kashiwara-shi, Osaka, 582-0005, Japan
  • Novo Nordisk Investigational Site
    Kawagoe-shi, Saitama, 350-0851, Japan
  • Novo Nordisk Investigational Site
    Kawaguchi-shi, Saitama, 332-0012, Japan
  • Novo Nordisk Investigational Site
    Kumamoto-shi, Kumamoto, 862-0965, Japan
  • Novo Nordisk Investigational Site
    Kumamoto, 862-0976, Japan
  • Novo Nordisk Investigational Site
    Mitaka-shi, Tokyo, 181-0013, Japan
  • Novo Nordisk Investigational Site
    Miyazaki, 880-0034, Japan
  • Novo Nordisk Investigational Site
    Nagano, 390-8621, Japan
  • Novo Nordisk Investigational Site
    Nakagami, Okinawa, 901-2393, Japan
  • Novo Nordisk Investigational Site
    Neyagawa-shi, Osaka, Japan
  • Novo Nordisk Investigational Site
    Niigata-shi, Niigata, 950 1104, Japan
  • Novo Nordisk Investigational Site
    Okawa-shi, Fukuoka, 831-0016, Japan
  • Novo Nordisk Investigational Site
    Osaka-shi, Osaka, 536-0001, Japan
  • Novo Nordisk Investigational Site
    Osaka, 569-1045, Japan
  • Novo Nordisk Investigational Site
    Ota-ku, Tokyo, 1430015, Japan
  • Novo Nordisk Investigational Site
    Saitama-shi, Saitama, 336-0967, Japan
  • Novo Nordisk Investigational Site
    Sendai-shi, Miyagi, 980-0021, Japan
  • Novo Nordisk Investigational Site
    Shimotsuke-shi, Tochigi, 329-0433, Japan
  • Novo Nordisk Investigational Site
    Tochigi, 323-0022, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 103-0027, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 103-0028, Japan
  • Novo Nordisk Investigational Site
    Tokyo, 113-8431, Japan
  • Novo Nordisk Investigational Site
    Tomigusuku-shi, Okinawa, 901-0243, Japan
  • Novo Nordisk Investigational Site
    Tomigusuku-shi, Okinawa, 901-0244, Japan
  • Novo Nordisk Investigational Site
    Yamaguchi-shi, Yamaguchi, 754-0002, Japan
10

References and documents

Publications

  • Watada H, Kaneko S, Komatsu M, Agner BR, Nishida T, Ranthe M, Nakamura J. Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial. Diabetes Obes Metab. 2019 Dec;21(12):2694-2703. doi: 10.1111/dom.13859. Epub 2019 Sep 17. PubMed 31423685 ↗
  • Komatsu M, Watada H, Kaneko S, Ross Agner BF, Nishida T, Kaku K. Efficacy and safety of the fixed-ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials. J Diabetes Investig. 2021 Sep;12(9):1610-1618. doi: 10.1111/jdi.13525. Epub 2021 Mar 24. PubMed 33595901 ↗
  • Watada H, Ross Agner BF, Doshi A, Bardtrum L, Ranthe MF, Billings LK. IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy. Diabetes Ther. 2020 Jan;11(1):331-339. doi: 10.1007/s13300-019-00730-y. Epub 2019 Nov 23. PubMed 31760599 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Nov 2017, 13 months.

Results were first posted in Mar 2019, 1 year 3 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2016
First posted
Sep 23, 2016
StartActual
Sep 21, 2016
Primary completionActual
Nov 17, 2017
CompletionActual
Nov 22, 2017
Results first posted
Mar 11, 2019
Last update
Apr 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02911948
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 23, 2016
Start date
Sep 21, 2016
Primary completion
Nov 17, 2017
Completion
Nov 22, 2017
Results posted
Mar 11, 2019
Last update
Apr 9, 2021

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Liraglutide

Start the discussion